The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
September 6th 2024
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 6, 2024.
Evolving Perspectives in Alzheimer Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, an...
September 16, 2024
Register Now!
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con...
November 12, 2024
Register Now!
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
Utility of Digital Twin AI-Generated Models to Improve Patient Selection in Alzheimer Trials
August 27th 2024Steve Herne, chief commercial officer at Unlearn, provided context on a recently conducted study assessing the company’s digital twin methodology AI tool to enhance the statistical certainty of Alzheimer trials.
NeuroVoices: Anthony Caggiano, MD, PhD, on Therapeutic Progress of Alzheimer Agent CT1812
August 21st 2024The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.
Promising Diagnostic Approaches Emerging for Brain Pathologies: James Leverenz, MD
August 16th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed new diagnostic techniques that show promise for advancing the understanding of brain pathologies like Alzheimer and Lewy Body diseases. [WATCH TIME: 3 minutes]
Potential of Newer Techniques to Diagnose Dementia with Lewy Bodies: James Leverenz, MD
August 15th 2024The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic talked about challenges of accurately diagnosing dementia with Lewy bodies as well as new methods that show promise in guiding treatment. [WATCH TIME: 3 minutes]
Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
August 14th 2024Peter Vanderklish, PhD, chief science officer at Spingogenix, commented on a recently initiated phase 2 trial assessing investigational SPG302, a synaptic-regenerative agent in development for Alzheimer disease.
Challenges in Early Diagnosis of Frontotemporal Dementia in Clinical Settings: Chris Berka
August 13th 2024The CEO and cofounder at Advanced Brain Monitoring talked about how the early diagnosis of frontotemporal dementia is often mistaken for Alzheimer disease, but advancements in neuropsychological assessments and biomarker identification may improve accuracy. [WATCH TIME: 4 minutes]
Tracking Neurodegenerative Disease Trajectories With EEG Biomarkers: Chris Berka
August 11th 2024The CEO and cofounder at Advanced Brain Monitoring discussed using EEG-based biomarkers to identify early markers that predict cognitive decline and aid in differential diagnosis for neurodegenerative diseases. [WATCH TIME: 4 minutes]
Adapting to Changes in Alzheimer Disease Trials and Therapeutics: Ivana Rubino, PhD, MSc
August 8th 2024The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen commented on challenges with conducting effective trials for Alzheimer disease and the potential research opportunities with newly approved novel treatments. [WATCH TIME: 6 minutes]
Insights From a Large-Scale Study on Differentiating Dementia Subtypes With EEG: Chris Berka
August 8th 2024The CEO and cofounder at Advanced Brain Monitoring talked about how exploring electroencephalography patterns can help differentiate between Alzheimer disease, Lewy body dementia, and frontotemporal dementia. [WATCH TIME: 3 minutes]
Impact of Blood Tests on Wait Times and Treatment in Alzheimer Disease: Soeren Mattke, MD, DSc
August 7th 2024The director of the Brain Health Observatory at the University of Southern California discussed how blood tests for Alzheimer disease could significantly reduce diagnostic wait times and improve treatment monitoring. [WATCH TIME: 4 minutes]
Mechanism of Action and Potential of Anti-Tau Agent BIIB080: Ivana Rubino, PhD, BSc
August 6th 2024The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen provided perspective on the promising development of BIIB080, a treatment thought to work by reducing forms of tau protein. [WATCH TIME: 4 minutes]